Clinical/Translational Cancer Immunotherapy

Homocitrullination of lysine residues mediated by myeloid-derived suppressor cells in the tumor environment is a target for cancer immunotherapy
Katherine W Cook, Wei Xue, Peter Symonds, Ian Daniels, Mohamed Gijon, David Boocock, Clare Coveney, Amanda K Miles, Sabaria Shah, Suha Atabani, Ruhul H Choudhury, Poonam Vaghela, Daisy Weston, Rachael L Metheringham, Victoria A Brentville, Lindy G Durrant

Journal for ImmunoTherapy of Cancer Jul 2021, 9 (7) e001910; DOI: 10.1136/jitc-2020-001910
Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal
Sho Isoyama, Shigeyuki Mori, Daisuke Sugiyama, Yasuhiro Kojima, Yasuko Tada, Kohei Shitara, Kunihiko Hinohara, Shingo Dan, Hiroyoshi Nishikawa

Journal for ImmunoTherapy of Cancer Aug 2021, 9 (8) e002279; DOI: 10.1136/jitc-2020-002279
Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumors
Robert H Vonderheide, Kimberly A Kraynyak, Anthony F Shields, Autumn J McRee, Jennifer M Johnson, Weijing Sun, Ashish V Chintakuntlawar, Jan Pawlicki, Albert J Sylvester, Trevor McMullan, Robert Samuels, Joseph J Kim, David Weiner, Jean D Boyer, Matthew P Morrow, Laurent Humeau, Jeffrey M Skolnik

Journal for ImmunoTherapy of Cancer Jul 2021, 9 (7) e003019; DOI: 10.1136/jitc-2021-003019
Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events
Bilal A Siddiqui, Jinesh S Gheeya, Rohit Goswamy, Tharakeswara K Bathala, Devaki Shilpa Surasi, Jianjun Gao, Amishi Shah, Matthew T Campbell, Pavlos Msaouel, Sangeeta Goswami, Jennifer Wang, Amado J Zurita, Eric Jonasch, Paul G Corn, Ana M Aparicio, Arlene O Siefker-Radtke, Padmanee Sharma, Sumit K Subudhi, Nizar Tannir

Journal for ImmunoTherapy of Cancer Jul 2021, 9 (7) e002850; DOI: 10.1136/jitc-2021-002850
Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial
Belén Sierra-Rodero, Alberto Cruz-Bermúdez, Ernest Nadal, Yago Garitaonaindía, Amelia Insa, Joaquín Mosquera, Joaquín Casal-Rubio, Manuel Dómine, Margarita Majem, Delvys Rodriguez-Abreu, Alex Martinez-Marti, Javier De Castro Carpeño, Manuel Cobo, Guillermo López Vivanco, Edel Del Barco, Reyes Bernabé Caro, Nuria Viñolas, Isidoro Barneto Aranda, Santiago Viteri, Bartomeu Massuti, Raquel Laza-Briviesca, Marta Casarrubios, Aránzazu García-Grande, Atocha Romero, Fernando Franco, Mariano Provencio

Journal for ImmunoTherapy of Cancer Aug 2021, 9 (8) e002804; DOI: 10.1136/jitc-2021-002804
Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab
James L Alexander, Hajir Ibraheim, Bhavisha Sheth, Jessica Little, Muhammad Saheb Khan, Camellia Richards, Nikki Hunter, Dharmisha Chauhan, Raguprakash Ratnakumaran, Kathleen McHugh, David J Pinato, Paul Nathan, Julia Choy, Shanthini M Crusz, Andrew Furness, Samra Turajlic, Lisa Pickering, James Larkin, Julian P Teare, Sophie Papa, Ally Speight, Anand Sharma, Nick Powell

Journal for ImmunoTherapy of Cancer Jul 2021, 9 (7) e002742; DOI: 10.1136/jitc-2021-002742
WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape
Chunwan Lu, Zhuoqi Liu, John D Klement, Dafeng Yang, Alyssa D Merting, Dakota Poschel, Thomas Albers, Jennifer L Waller, Huidong Shi, Kebin Liu

Journal for ImmunoTherapy of Cancer Jul 2021, 9 (7) e002624; DOI: 10.1136/jitc-2021-002624
Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response
Lele Zhang, Jiacheng Huang, Xiaona Chen, Caixu Pan, Yong He, Rong Su, Danjing Guo, Shengyong Yin, Shuai Wang, Lin Zhou, Jianxiang Chen, Shusen Zheng, Yiting Qiao

Journal for ImmunoTherapy of Cancer Aug 2021, 9 (8) e003132; DOI: 10.1136/jitc-2021-003132
Exploiting off-target effects of estrogen deprivation to sensitize estrogen receptor negative breast cancer to immune killing
Benjamin Wolfson, Michelle R Padget, Jeffrey Schlom, James W Hodge

Journal for ImmunoTherapy of Cancer Jul 2021, 9 (7) e002258; DOI: 10.1136/jitc-2020-002258
Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies
Gabrielle Leclercq, Hélène Haegel, Anneliese Schneider, Anna Maria Giusti, Estelle Marrer-Berger, Christophe Boetsch, Antje-Christine Walz, Vesna Pulko, Johannes Sam, John Challier, Cristiano Ferlini, Alex Odermatt, Pablo Umaña, Marina Bacac, Christian Klein

Journal for ImmunoTherapy of Cancer Jul 2021, 9 (7) e002582; DOI: 10.1136/jitc-2021-002582

Main menu

Clinical/Translational Cancer Immunotherapy

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Clinical/Translational Cancer Immunotherapy

Pages